/PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular LymphomaUSA - EnglishUSA - EnglishJapan - JapaneseUSA - DeutschAPAC - EnglishKorea - 한국어USA - españolUSA - Français
NEWS
PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular LymphomaUSA - EnglishUSA - EnglishJapan - JapaneseUSA - DeutschAPAC - EnglishKorea - 한국어USA - españolUSA - Français
PRNewswire
2024/12/19PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular LymphomaUSA - EnglishUSA - EnglishJapan - JapaneseUSA - DeutschAPAC - EnglishKorea - 한국어USA - españolUSA - Français
PMB_x_IFLI_Logo
Summary
/PRNewswire/ -- PeproMene Bio, Inc. (PMB) has announced an $11M investment from the Institute for Follicular Lymphoma Innovation (IFLI) to support the clinical...